1型神经纤维瘤病中非典型神经纤维瘤性肿瘤及其恶变为恶性外周神经鞘瘤的组织病理学评估共识概述
1型神经纤维瘤病(NF1)患者一生中8%至15%发生恶性外周神经鞘瘤(MPNST),预测恶变在临床和组织学上具有挑战性。2016年10月共识会议后,本文概述了神经纤维瘤恶变的组织病理学特征和分子机制,提出「生物学潜能不确定的非典型神经纤维瘤性肿瘤(ANNUBP)」这一术语用于至少具备2项关注特征的病变,并建议额外取样、临床相关性和可能的专家病理会诊。
要点
- 单独的核异型性通常无显著意义。
- 异型性伴神经纤维瘤结构丧失、高细胞密度和/或核分裂活性>1/50但<3/10高倍视野提示恶性担忧。
- 至少具备2项上述特征者诊断为ANNUBP,应额外取样、临床相关性和可能的专家会诊。
核心结论
- 提出ANNUBP术语用于至少具备2项关注特征(异型性、结构丧失、高细胞密度、核分裂活性>1/50但<3/10 HPF)的病变,以规范诊断并提示额外取样和专家会诊。
研究设计与样本
- 基于2016年10月共识会议的概述,归纳NF1患者神经纤维瘤恶变为MPNST的组织病理学特征和分子机制。
- 共识概述,未报告系统检索或样本量。
主要发现
- NF1患者一生中8%至15%发生MPNST,恶变通常来自丛状神经纤维瘤。
- 单独的核异型性通常无显著意义。
- 异型性伴神经纤维瘤结构丧失、高细胞密度和/或核分裂活性>1/50但<3/10高倍视野提示恶性担忧。
- 大多数起源于神经纤维瘤的MPNST为高级别肉瘤,诊断困难不大;罕见无坏死肿瘤伴3-9个核分裂/10高倍视野可识别为低级别变异型。
- 神经纤维瘤含大量S100蛋白/SOX10阳性施万细胞和CD34阳性成纤维细胞,两者在MPNST中减少或缺失;p16/CDKN2A表达缺失、Ki67标记升高和弥漫核p53阳性也见于MPNST,部分已见于ANNUBP;三甲基化组蛋白H3K27表达完全缺失潜在更可靠,约半数MPNST可免疫组化检测到。
关键数值与推荐
- ANNUBP定义为至少具备2项以下特征:异型性、神经纤维瘤结构丧失、高细胞密度、核分裂活性>1/50但<3/10高倍视野。
- 低级别MPNST变异型:无坏死肿瘤伴3-9个核分裂/10高倍视野。
- 推荐对ANNUBP诊断进行额外取样、临床相关性和可能的专家病理会诊。
临床怎么用
- 对神经纤维瘤病变评估时,单独核异型性不足以诊断恶性,需综合结构、细胞密度和核分裂活性。
- 符合ANNUBP标准时应额外取样、结合临床,并考虑专家病理会诊以区分非典型神经纤维瘤和低级别MPNST。
- 免疫组化S100/SOX10、CD34、p16/CDKN2A、Ki67、p53和H3K27me3有助于评估恶变。
局限性
- 当前此类肿瘤被不一致地诊断为非典型神经纤维瘤或低级别MPNST。
- 需要更多临床病理、影像和遗传学关联研究以提高对恶变的理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with neurofibromatosis 1 (NF1) develop multiple neurofibromas, with 8% to 15% of patients experiencing malignant peripheral nerve sheath tumor (MPNST) during their lifetime. Prediction of transformation, typically from plexiform neurofibroma, is clinically and histologically challenging. In this overview, after a consensus meeting in October 2016, we outline the histopathologic features and molecular mechanisms involved in the malignant transformation of neurofibromas. Nuclear atypia alone is generally insignificant. However, with atypia, loss of neurofibroma architecture, high cellularity, and/or mitotic activity >1/50 but <3/10 high-power fields, the findings are worrisome for malignancy. We propose the term "atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBP)" for lesions displaying at least 2 of these features. This diagnosis should prompt additional sampling, clinical correlation, and possibly, expert pathology consultation. Currently, such tumors are diagnosed inconsistently as atypical neurofibroma or low-grade MPNST. Most MPNSTs arising from neurofibromas are high-grade sarcomas and pose little diagnostic difficulty, although rare nonnecrotic tumors with 3-9 mitoses/10 high-power fields can be recognized as low-grade variants. Although neurofibromas contain numerous S100 protein/SOX10-positive Schwann cells and CD34-positive fibroblasts, both components are reduced or absent in MPNST. Loss of p16/CDKN2A expression, elevated Ki67 labeling, and extensive nuclear p53 positivity are also features of MPNST that can to some degree already occur in atypical neurofibromatous neoplasms of uncertain biologic potential. Complete loss of trimethylated histone 3 lysine 27 expression is potentially more reliable, being immunohistochemically detectable in about half of MPNSTs. Correlated clinicopathological, radiologic, and genetic studies should increase our understanding of malignant transformation in neurofibromas, hopefully improving diagnosis and treatment soon.
引用
- Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol. 2017. PMID: 28551330. doi:10.1016/j.humpath.2017.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。